Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 6,860 matching trials from the live ClinicalTrials.gov search.

Filters: Orlando, Florida Clear all

Conditions: Hepatitis C, HCV, Chronic Hepatitis C Infection, Hepatitis C Genotype 1
Interventions: ABT-450, ABT-072, ABT-333, Ritonavir, Peginterferon alpha-2a, Ribavirin, Placebo; Drug · Other
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 25
States / cities: Phoenix, Arizona • Anaheim, California • La Jolla, California + 19 more

Conditions: Limb Deformities, Congenital, Upper Extremity Deformities, Congenital, Congenital Abnormalities
Interventions: 3D myoelectric prosthetic device; Device
Lead sponsor: Orlando Health, Inc.; Other
Eligibility: 7 Years to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Overweight, Obesity
Interventions: Macupatide, Eloralintide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 40
States / cities: Chandler, Arizona • Scottsdale, Arizona • Tucson, Arizona + 37 more

Conditions: Insomnia
Interventions: Ramelteon, zolpidem and placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 65 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 6
States / cities: Costa Mesa, California • San Diego, California • Miami, Florida + 3 more

Conditions: Schizophrenia, Autism-Related Irritability
Interventions: KarXT, KarX-EC; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 56
States / cities: Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 47 more

Conditions: Bipolar Disorder
Interventions: placebo oral capsules, ziprasidone oral capsules; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 46
States / cities: Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 30 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Revefenacin, Tiotropium, Revefenacin Placebo, Tiotropium Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 40 Years and older
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 76
States / cities: Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more

Conditions: Ulcerative Colitis (UC)
Interventions: TD-1473 Dose A, TD-1473 Dose B, TD-1473 Dose C, Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 18 Years and older
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 38
States / cities: Chula Vista, California • La Jolla, California • Lancaster, California + 34 more

Conditions: Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma, Immature Teratoma, Malignant Teratoma, Mixed Germ Cell Tumor, Pineal Region Germ Cell Tumor, Pineal Region Immature Teratoma, Pineal Region Yolk Sac Tumor, Suprasellar Germ Cell Tumor
Interventions: Biospecimen Collection, Carboplatin, Etoposide, Filgrastim, Ifosfamide, Magnetic Resonance Imaging, Mesna, Pegfilgrastim, Peripheral Blood Stem Cell Transplantation, Questionnaire Administration, Radiation Therapy, Second-Look Surgery, Thiotepa; Procedure · Drug · Biological + 2 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 29 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 152
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 120 more

Conditions: Solid Tumors
Interventions: mRNA-4157, Pembrolizumab, SoC Treatment; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 10
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 7 more

Conditions: Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Unresectable Dedifferentiated Liposarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
Interventions: Biospecimen Collection, Diagnostic Imaging Testing, Doxorubicin, Echocardiography Test, Multigated Acquisition Scan, Pembrolizumab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 258
States / cities: Phoenix, Arizona • Tucson, Arizona • Dublin, California + 209 more

Conditions: Hepatic Encephalopathy
Interventions: Rifaximin SSD, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 517 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 90
States / cities: Homewood, Alabama • Chandler, Arizona • Sun City, Arizona + 70 more

Conditions: Hepatic Impairment
Interventions: Treprostinil Palmitil Inhalation Powder; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Lake Forest, California • San Dimas, California • Orlando, Florida + 1 more

Conditions: Hormone Receptor Positive Breast Cancer, HER-2 Positive Breast Cancer
Interventions: Abemaciclib, Trastuzumab, Fulvestrant, Standard of Care Single Agent Chemotherapy; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 32
States / cities: Bakersfield, California • Fullerton, California • Los Angeles, California + 22 more

Conditions: Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Colorectal Cancer, Endometrial Cancer, Urothelial Carcinoma (UC), Breast Cancer
Interventions: STRO-006, Pembrolizumab; Drug
Lead sponsor: Sutro Biopharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 6
States / cities: Orlando, Florida • Boston, Massachusetts • Oklahoma City, Oklahoma + 3 more

Conditions: Cytomegalovirus (CMV)
Interventions: Maribavir, Ganciclovir, Valganciclovir, Foscarnet, Cidofovir; Drug
Lead sponsor: Shire; Industry
Eligibility: 12 Years and older
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 47
States / cities: Birmingham, Alabama • Tucson, Arizona • Duarte, California + 35 more

Conditions: Pneumonia
Interventions: clarithromycin extended release (ER), azithromycin SR; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years and older
Enrollment: 504 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 36
States / cities: Birmingham, Alabama • Haleyville, Alabama • Montgomery, Alabama + 24 more

Conditions: Obesity, Overweight
Interventions: EndoZip System, OverStitch Endoscopic Suturing System (ESG); Device
Lead sponsor: Nitinotes Surgical Ltd.; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Los Angeles, California • Orlando, Florida • New York, New York

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
Interventions: Not listed
Lead sponsor: Precision Therapeutics; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 36
States / cities: Irvine, California • Los Angeles, California • New Haven, Connecticut + 30 more

Conditions: Healthy, Renal Insufficiency
Interventions: LY3437943; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Tustin, California • Miami, Florida • Orlando, Florida + 1 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Sotatercept, Placebo; Drug · Other
Lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA; Industry
Eligibility: 18 Years and older
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 28
States / cities: Scottsdale, Arizona • Tucson, Arizona • La Jolla, California + 23 more

Conditions: Ulcerative Colitis
Interventions: PF-06651600 or Placebo, PF-06700841 or Placebo, PF-06700841, PF-06651600; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 60
States / cities: Dothan, Alabama • Long Beach, California • Los Angeles, California + 26 more

Conditions: HIV Infections
Interventions: Tipranavir, Ritonavir; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: Not listed
Timeline: Started 2004
U.S. locations: 115
States / cities: Anniston, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 74 more

Conditions: Breast Cancer
Interventions: BIIB021, exemestane (Aromasin); Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 19
States / cities: Alabaster, Alabama • Encinitas, California • Gilroy, California + 15 more

Search by objective public record fields.

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072

Evaluation of 3D Printed Myoelectric Prosthetic Devices in Children With Upper Congenital Limb Deficiency

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Safety of Ramelteon in Elderly Subjects

A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents

Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder

Phase 4 COPD and Suboptimal Inspiratory Flow Rate

Efficacy & Safety of TD-1473 in Ulcerative Colitis

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis

A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer

Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic

Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir

A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Clarithromycin Extended Release for the Treatment of Pneumonia in Adult Patients

Comparing the Efficacy and Safety of the EndoZip System and Apollo ESG in Obese Patients

Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer

A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function

Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)

Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection

Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding